| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911137 | Lung Cancer | 2014 | 6 Pages |
Abstract
Incidence of brain and bone metastases was not different between EGFR+, KRAS+ and WT patients. Post brain metastases survival, time from mNSCLC diagnosis to metastatic bone disease and 1st SRE did not differ either. Post metastatic bone disease survival was significantly longer in EGFR+ patients. Although prevention of SRE's is important for all patients, the latter finding calls for a separate study for SRE preventing agents in EGFR+ patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
L.E.L. Hendriks, E.F. Smit, B.A.H. Vosse, W.W. Mellema, D.A.M. Heideman, G.P. Bootsma, M. Westenend, C. Pitz, G.J. de Vries, R. Houben, K. Grünberg, M. Bendek, E.-J.M. Speel, A.-M.C. Dingemans,